Therapeutic effect of adjunctive continuous theta burst stimulation on orbitofrontal cortex in patients of obsessive compulsive disorder

Efficacy of adjunctive continuous theta burst stimulation(cTBS) over orbitofrontal cortex in obsessive compulsive disorder as measured by event related potential:A randomised sham controlled study - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057994

Enrollment

Registered

2023-09-25

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F422- Mixed obsessional thoughts and acts

Interventions

Intervention1: Double cone coil continuous theta burst stimulation active: cTBS would be performed using a Magstim Rapid2 Plus1 magnetic stimulator (Magstim Inc, Wales, UK) with a double-cone coil. Be

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Obsessive-Compulsive Disorder using Diagnostic Criteria for Research (DCR) of ICD 11 DCR supplemented with ICD 11 for Mortality and Morbidity Statistics (February 2022 edition) 2. Y-BOCS score of 15 or above 3. Age between 18-60 years of either sex 4. Right-handed 5. Patients giving written informed consent 6. Patient should be on antiobsessive medication for at least 4 weeks

Exclusion criteria

Exclusion criteria: 1. Co-morbid severe depression as measured by a HAM-D score of 23 or more 2. Patients with co-morbid neurological or any other psychiatric disorder 3. History of epilepsy, significant head injury or any neurosurgical procedure. 4. Patient with presence of pacemaker or other electronic implant, metal or magnetic objects in the brain.

Design outcomes

Primary

Measure	Time frame
Reduction in Y-BOCS score after application of cTBSTimepoint: Reduction in Y-BOCS score as assessed at baseline, at 2 weeks and 6 weeks	—

Secondary

Measure	Time frame
Changes in the amplitude & latency of the ERN component of ERP on GO/NO-GO taskTimepoint: Changes in the amplitude & latency of the ERN component of ERP on GO/NO-GO task will be assessed at baseline & 2 weeks	—

Countries

India

Contacts

Public ContactDr Aniruddha Mukherjee

Central Institute of Psychiatry

dr_aniruddha@hotmail.com9474413598

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026